BG-12 significantly reduced brain lesions in multiple sclerosis - Biogen Idec announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of...



Tovaxin(R) demonstrates reduction in disability, relapse risk and myelin T-cell reactivity in patients with Multiple Sclerosis
Opexa Therapeutics, Inc. announced additional positive data from the company's Phase IIb TERMS clinical trial (Tovaxin(R) for Early Relapsing Multiple Sclerosis). The latest analysis focused on...



Campath may benefit Multiple Sclerosis patients -

source: MSRC

To receive weekly updates on MS News: Register Here

.
Leaving comments is a great way to get others involved with the topic.
Please feel free to leave your comment(s).
============================================